{"id":23609,"date":"2026-04-22T01:21:00","date_gmt":"2026-04-22T01:21:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/"},"modified":"2026-04-22T01:21:00","modified_gmt":"2026-04-22T01:21:00","slug":"%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/","title":{"rendered":"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a"},"content":{"rendered":"

\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde<\/span>2026\u5e744\u670822\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u516d\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092026\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5242Alrizomadlin\uff08APG-115\uff09\u3002<\/p>\n

\n

\n <\/a><\/p>\n

\n <\/p>\n<\/div>\n

\u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”\u8fd9\u5c06\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u79cd\u6709\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u7814\u7a76\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\uff0c\u518d\u6b21\u5370\u8bc1\u4e86\u56fd\u9645\u5b66\u672f\u754c\u5bf9\u516c\u53f8\u539f\u7814\u54c1\u79cd\u4e34\u5e8a\u4ef7\u503c\u7684\u9ad8\u5ea6\u8ba4\u53ef\u3002\u6211\u4eec\u671f\u5f85\u5728\u4f1a\u8bae\u671f\u95f4\u4e3a\u5927\u5bb6\u5206\u4eab\u66f4\u4e3a\u8be6\u5b9e\u7684\u6570\u636e\uff0c\u5e76\u7ee7\u7eed\u52a0\u901f\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002”<\/p>\n

\u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4aASCO\u5e74\u4f1a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55\u5305\u62ec\uff1a<\/p>\n

\u5feb\u901f\u53e3\u5934\u62a5\u544a<\/p>\n

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u6cbb\u7597\u6dcb\u7cfb\u6025\u53d8\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027B\u7ec6\u80de\u524d\u4f53\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005
\u6458\u8981\u7f16\u53f7\uff1a6513
\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1<\/p>\n

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4e8c\u7ebf\u6cbb\u7597\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u6700\u65b0\u7597\u6548\u548c\u5b89\u5168\u6027\u6570\u636e
\u6458\u8981\u7f16\u53f7\uff1a6510
\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7eac\u660e\u6559\u6388\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u534f\u548c\u533b\u9662\u8840\u6db2\u79d1<\/p>\n

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed\/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Alrizomadlin\uff08APG-115\uff09\u5355\u836f\u6216\u8054\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7597\u590d\u53d1\/\u8f6c\u79fb\u6027\u6a2a\u7eb9\u808c\u8089\u7624\uff08RMS\uff09\u6216\u5176\u4ed6\u8f6f\u7ec4\u7ec7\u8089\u7624\uff08STSs\uff09\u513f\u7ae5\u60a3\u8005
\u6458\u8981\u7f16\u53f7\uff1a10012
\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u513f\u7ae5\u80bf\u7624II\uff08Pediatric Oncology II\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e745\u670830\u65e5 8:00\u20139:30\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e745\u670830\u65e5 21:00\u201322:30\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f20\u7ffc\u9ddf\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3\u513f\u7ae5\u80bf\u7624\u79d1\uff0c\u534e\u5357\u80bf\u7624\u5b66\u56fd\u5bb6\u91cd\u70b9\u5b9e\u9a8c\u5ba4\uff0c\u80bf\u7624\u533b\u5b66\u534f\u540c\u521b\u65b0\u4e2d\u5fc3<\/p>\n

\u58c1\u62a5\u5c55\u793a<\/p>\n

Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7597\u7425\u73c0\u9178\u8131\u6c22\u9176\u7f3a\u9677\u578b\uff08SDH-\uff09\u80bf\u7624\u60a3\u8005\u7684\u6700\u65b0\u4e34\u5e8a\u548c\u8f6c\u5316\u7814\u7a76\u7ed3\u679c
\u6458\u8981\u7f16\u53f7\uff1a11539
\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8089\u7624\uff08Sarcoma\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e746\u67081\u65e5 13:30\u201316:30\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e746\u67082\u65e5 \u51cc\u66682:30\u20135:30\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1a\u90b1\u6d77\u6ce2\u6559\u6388\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3\uff0c\u534e\u5357\u80bf\u7624\u5b66\u56fd\u5bb6\u91cd\u70b9\u5b9e\u9a8c\u5ba4\uff0c\u80bf\u7624\u533b\u5b66\u534f\u540c\u521b\u65b0\u4e2d\u5fc3<\/p>\n

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u6cbb\u7597\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u8fdb\u884c\u4e2d\u7684POLARIS-2\u8bd5\u9a8c
\u6458\u8981\u7f16\u53f7\uff1aTPS6608
\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1<\/p>\n

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): GLORA trial in progress
\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7597\u65e2\u5f80\u7ecf\u6cbb\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027\u3001\u968f\u673a\u3001III\u671f\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\uff1a\u6b63\u5728\u8fdb\u884c\u4e2d\u7684GLORA\u8bd5\u9a8c
\u6458\u8981\u7f16\u53f7\uff1aTPS7101
\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a
\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u6dcb\u5df4\u7624\u548c\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia\uff09
\u62a5\u544a\u65f6\u95f4\uff1a
2026\u5e746\u67081\u65e5 9:00\u201312:00\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff09
2026\u5e746\u67081\u65e5 22:00\u2013\u6b21\u65e5\u51cc\u66681:00\uff08\u5317\u4eac\u65f6\u95f4\uff09
\u7b2c\u4e00\u4f5c\u8005\uff1aMatthew Steven Davids, MD\uff0c\u7f8e\u56fd\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662<\/p>\n

\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/p>\n

\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u662f\u4e00\u5bb6\u7efc\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u521b\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u80bf\u7624\u9886\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e30\u5bcc\u7684\u521b\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\u3001\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5242\u3002<\/p>\n

\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u5df2\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u4f34\u6709T315I\u7a81\u53d8\u7684\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5bf9\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8be5\u836f\u7269\u6240\u6709\u83b7\u6279\u9002\u5e94\u75c7\u5747\u5df2\u88ab\u7eb3\u5165\u4e2d\u56fd\u56fd\u5bb6\u533b\u4fdd\u836f\u54c1\u76ee\u5f55\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9879\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u5206\u522b\u4e3a\uff1a\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597\u65b0\u8bca\u65ad\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597\u7ecf\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8bc4\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7597SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002<\/p>\n

\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u79cd\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u4e8e\u6cbb\u7597\u591a\u79cd\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5242\u3002\u5229\u751f\u59a5\u00ae\u5df2\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u79cd\u5305\u62ec\u5e03\u9c81\u987f\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5242\u5728\u5185\u7684\u7cfb\u7edf\u6cbb\u7597\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9a\u76db\u533b\u836f\u6b63\u5728\u5f00\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9879\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u5206\u522b\u4e3a\uff1a\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32MEA\u8bb8\u53ef\u7684\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u8054\u5408BTK\u6291\u5236\u5242\u6cbb\u7597\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5242\u6cbb\u7597\u8d85\u8fc712\u4e2a\u6708\u4e14\u5e94\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u83b7\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u8bb8\u53ef\u7684\u8bc4\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7ebf\u6cbb\u7597\u65b0\u8bca\u65ad\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002<\/p>\n

\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0e\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u4e1c\u3001\u8f89\u745e\u3001\u4fe1\u8fbe\u7b49\u4f17\u591a\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u8fbe\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u65f6\u4e0e\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u3001\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b66\u7b49\u5b66\u672f\u673a\u6784\u5efa\u7acb\u7814\u53d1\u5408\u4f5c\u5173\u7cfb\u3002\u5982\u9700\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u00a0https:\/\/ascentage.com\/<\/a><\/p>\n

\u524d\u77bb\u6027\u58f0\u660e<\/p>\n

\u672c\u65b0\u95fb\u7a3f\u5305\u542b\u6839\u636e\u7f8e\u56fd\u300a1995\u5e74\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7ecf\u4fee\u8ba2\u7684\u300a1933\u5e74\u8bc1\u5238\u6cd5\u300b\u7b2c27A\u6761\u548c\u300a1934\u5e74\u8bc1\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u6761\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9648\u8ff0\u3002\u9664\u5386\u53f2\u4e8b\u5b9e\u9648\u8ff0\u5916\uff0c\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u6240\u6709\u5185\u5bb9\u5747\u53ef\u80fd\u6784\u6210\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u5305\u62ec\u4e9a\u76db\u533b\u836f\u5bf9\u672a\u6765\u4e8b\u4ef6\u3001\u7ecf\u8425\u6210\u679c\u6216\u8d22\u52a1\u72b6\u51b5\u6240\u53d1\u8868\u7684\u610f\u89c1\u3001\u9884\u671f\u3001\u4fe1\u5ff5\u3001\u8ba1\u5212\u3001\u76ee\u6807\u3001\u5047\u8bbe\u6216\u9884\u6d4b\u3002<\/p>\n

\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\u53d7\u5230\u8bf8\u591a\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u7684\u5f71\u54cd\uff0c\u5177\u4f53\u5185\u5bb9\u5df2\u5728\u4e9a\u76db\u533b\u836f\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8be6\u7ec6\u8bf4\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7ecf\u4fee\u8ba2\u7684F-1\u8868\u683c\u6ce8\u518c\u8bf4\u660e\u4e66\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684”\u98ce\u9669\u56e0\u7d20”\u548c”\u5173\u4e8e\u524d\u77bb\u6027\u58f0\u660e\u7684\u8b66\u793a\u58f0\u660e”\u7ae0\u8282\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u53d1\u884c\u4e0a\u5e02\u62db\u80a1\u4e66\u4e2d\u7684”\u524d\u77bb\u6027\u58f0\u660e”\u3001”\u98ce\u9669\u56e0\u7d20”\u7ae0\u8282\uff0c\u4ee5\u53ca\u6211\u4eec\u4e0d\u65f6\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u8fd9\u4e9b\u56e0\u7d20\u53ef\u80fd\u5bfc\u81f4\u5b9e\u9645\u4e1a\u7ee9\u3001\u8fd0\u8425\u6c34\u5e73\u3001\u7ecf\u8425\u6210\u679c\u6216\u6210\u5c31\u4e0e\u524d\u77bb\u6027\u9648\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u672c\u524d\u77bb\u6027\u58f0\u660e\u4e2d\u7684\u9648\u8ff0\u4e0d\u6784\u6210\u516c\u53f8\u7ba1\u7406\u5c42\u7684\u5229\u6da6\u9884\u6d4b\u3002<\/p>\n

\u56e0\u6b64\uff0c\u8be5\u7b49\u524d\u77bb\u6027\u9648\u8ff0\u4e0d\u5e94\u88ab\u89c6\u4e3a\u5bf9\u672a\u6765\u4e8b\u4ef6\u7684\u9884\u6d4b\u3002\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u57fa\u4e8e\u4e9a\u76db\u533b\u836f\u5f53\u524d\u5bf9\u672a\u6765\u53d1\u5c55\u53ca\u5176\u6f5c\u5728\u5f71\u54cd\u7684\u9884\u671f\u548c\u5224\u65ad\uff0c\u4e14\u4ec5\u4ee3\u8868\u622a\u81f3\u9648\u8ff0\u53d1\u8868\u4e4b\u65e5\u7684\u89c2\u70b9\u3002\u65e0\u8bba\u51fa\u73b0\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u4e9a\u76db\u533b\u836f\u5747\u65e0\u4e49\u52a1\u66f4\u65b0\u6216\u4fee\u8ba2\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u3002<\/p>\n

SOURCE \u4e9a\u76db\u533b\u836f<\/p>","protected":false},"excerpt":{"rendered":"

\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u516d\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092026\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5242Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”\u8fd9\u5c06\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u79cd\u6709\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u7814\u7a76\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\uff0c\u518d\u6b21\u5370\u8bc1\u4e86\u56fd\u9645\u5b66\u672f\u754c\u5bf9\u516c\u53f8\u539f\u7814\u54c1\u79cd\u4e34\u5e8a\u4ef7\u503c\u7684\u9ad8\u5ea6\u8ba4\u53ef\u3002\u6211\u4eec\u671f\u5f85\u5728\u4f1a\u8bae\u671f\u95f4\u4e3a\u5927\u5bb6\u5206\u4eab\u66f4\u4e3a\u8be6\u5b9e\u7684\u6570\u636e\uff0c\u5e76\u7ee7\u7eed\u52a0\u901f\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” \u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4aASCO\u5e74\u4f1a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u5934\u62a5\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u6cbb\u7597\u6dcb\u7cfb\u6025\u53d8\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027B\u7ec6\u80de\u524d\u4f53\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7f16\u53f7\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u62a5\u544a\u65f6\u95f4\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u65f6\u95f4\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with […]<\/p>\n","protected":false},"author":0,"featured_media":23610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-23609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\n\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u30102026-asco\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u516d\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092026\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5242Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”\u8fd9\u5c06\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u79cd\u6709\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u7814\u7a76\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\uff0c\u518d\u6b21\u5370\u8bc1\u4e86\u56fd\u9645\u5b66\u672f\u754c\u5bf9\u516c\u53f8\u539f\u7814\u54c1\u79cd\u4e34\u5e8a\u4ef7\u503c\u7684\u9ad8\u5ea6\u8ba4\u53ef\u3002\u6211\u4eec\u671f\u5f85\u5728\u4f1a\u8bae\u671f\u95f4\u4e3a\u5927\u5bb6\u5206\u4eab\u66f4\u4e3a\u8be6\u5b9e\u7684\u6570\u636e\uff0c\u5e76\u7ee7\u7eed\u52a0\u901f\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” \u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4aASCO\u5e74\u4f1a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u5934\u62a5\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u6cbb\u7597\u6dcb\u7cfb\u6025\u53d8\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027B\u7ec6\u80de\u524d\u4f53\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7f16\u53f7\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u62a5\u544a\u65f6\u95f4\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u65f6\u95f4\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u30102026-asco\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T01:21:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/\",\"name\":\"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg\",\"datePublished\":\"2026-04-22T01:21:00+00:00\",\"dateModified\":\"2026-04-22T01:21:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg\",\"width\":144,\"height\":54},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u30102026-asco\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\/","og_locale":"en_US","og_type":"article","og_title":"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN","og_description":"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2026\u5e744\u670822\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u7684\u516d\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u90092026\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u4e09\u4e2a\u91cd\u70b9\u54c1\u79cd\u5206\u522b\u4e3a\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u3001\u4e2d\u56fd\u9996\u4e2a\u83b7\u6279\u4e0a\u5e02\u7684\u56fd\u4ea7\u539f\u521bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff09\u548cMDM2-p53\u6291\u5236\u5242Alrizomadlin\uff08APG-115\uff09\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASCO\u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6700\u91cd\u8981\u3001\u6700\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u6700\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002\u672c\u5c4aASCO\u5e74\u4f1a\u5c06\u4e8e5\u670829\u65e5\u81f36\u67082\u65e5\uff08\u7f8e\u56fd\u5f53\u5730\u65f6\u95f4\uff09\u5728\u829d\u52a0\u54e5McCormick\u4f1a\u8bae\u4e2d\u5fc3\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u7ed3\u5408\u7684\u5f62\u5f0f\u4e3e\u529e\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”\u8fd9\u5c06\u662f\u4e9a\u76db\u533b\u836f\u8fde\u7eed\u7b2c\u4e5d\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\uff0c\u5f88\u9ad8\u5174\u80fd\u591f\u53c8\u4e00\u6b21\u7ad9\u5728\u8fd9\u4e00\u56fd\u9645\u9876\u5c16\u5b66\u672f\u821e\u53f0\u5c55\u793a\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u4e0e\u7814\u53d1\u5b9e\u529b\u3002\u4eca\u5e74\uff0c\u516c\u53f8\u5728\u7814\u54c1\u79cd\u6709\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u7814\u7a76\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a\uff0c\u518d\u6b21\u5370\u8bc1\u4e86\u56fd\u9645\u5b66\u672f\u754c\u5bf9\u516c\u53f8\u539f\u7814\u54c1\u79cd\u4e34\u5e8a\u4ef7\u503c\u7684\u9ad8\u5ea6\u8ba4\u53ef\u3002\u6211\u4eec\u671f\u5f85\u5728\u4f1a\u8bae\u671f\u95f4\u4e3a\u5927\u5bb6\u5206\u4eab\u66f4\u4e3a\u8be6\u5b9e\u7684\u6570\u636e\uff0c\u5e76\u7ee7\u7eed\u52a0\u901f\u5168\u7403\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” \u4e9a\u76db\u533b\u836f\u5c06\u5728\u672c\u5c4aASCO\u5e74\u4f1a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55\u5305\u62ec\uff1a \u5feb\u901f\u53e3\u5934\u62a5\u544a Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408\u8d1d\u6797\u59a5\u6b27\u5355\u6297\u6cbb\u7597\u6dcb\u7cfb\u6025\u53d8\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML-LBP\uff09\u6216\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027B\u7ec6\u80de\u524d\u4f53\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ BCP-ALL\uff09\u60a3\u8005\u6458\u8981\u7f16\u53f7\uff1a6513\u5c55\u793a\u5f62\u5f0f\uff1a\u5feb\u901f\u53e3\u5934\u62a5\u544a\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u2014\u2014\u767d\u8840\u75c5\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\u53ca\u540c\u79cd\u5f02\u4f53\u79fb\u690d\uff08Hematologic Malignancies\u2014Leukemia, MDS, and Allotransplant\uff09\u62a5\u544a\u65f6\u95f4\uff1a2026\u5e745\u670830\u65e5 13:15\u201314:45\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092026\u5e745\u670831\u65e5 \u51cc\u66682:15\u20133:45\uff08\u5317\u4eac\u65f6\u95f4\uff09\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u56fd\u5fb7\u514b\u8428\u65af\u5927\u5b66MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with […]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u30102026-asco\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\/","og_site_name":"Money Compass CN","article_published_time":"2026-04-22T01:21:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/","url":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/","name":"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg","datePublished":"2026-04-22T01:21:00+00:00","dateModified":"2026-04-22T01:21:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2026\/04\/Ascentage_APAC_Logo-dFMJwt.jpeg","width":144,"height":54},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902026-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%85%b6%e4%b8%ad%e4%b8%89%e9%a1%b9%e8%8e%b7%e5%bf%ab%e9%80%9f%e5%8f%a3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u30102026 ASCO\u3011\u4e9a\u76db\u533b\u836f\u591a\u9879\u7814\u7a76\u5165\u9009\uff0c\u5176\u4e2d\u4e09\u9879\u83b7\u5feb\u901f\u53e3\u5934\u62a5\u544a"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/23609"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=23609"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/23609\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/23610"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=23609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=23609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=23609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}